Application of an Optimized Tape Stripping Method for the Bioequivalence Assessment of Topical Acyclovir Creams
This study indicates the application of tape stripping (TS) for bioequivalence (BE) assessment of a topical cream product containing 5% acyclovir. A TS method, previously used successfully to assess BE of topical clobetasol propionate and clotrimazole formulations, was used to assess BE of an acyclovir cream (5%) formulation as well as a diluted acyclovir formulation (1.5%) applied to the skin of healthy humans. An appropriate application time was established by conducting a dose duration study using the innovator product, Zovirax® cream. Transepidermal water loss was measured and used to normalize thicknesses between subjects. The area under the curve (AUC) from a plot of amount of acyclovir/strip vs cumulative fraction of stratum corneum (SC) removed was calculated for each application site. BE was assessed using Fieller’s theorem in accordance with FDA’s guidance for assessment of BE of topical corticosteroids. Adco-acyclovir cream (5%) was found to be BE to Zovirax® cream, where the mean test/reference (T/R) ratio of the AUC’s was 0.96 and the bioequivalence interval using a 90% confidence interval was 0.91–1.01 with a statistical power > 95%, whereas the diluted test product fell outside the BE acceptance criteria with T/R ratio of AUC of 0.23 and a 90% CI of 0.20–0.26. This study indicates that the data resulting from the application of this TS procedure has reinforced the potential for its use to assess BE of topical drug products intended for local action, thereby obviating the necessity to undertake clinical trials in patients.
KEY WORDSacyclovir cream topical dosage forms local action bioequivalence acceptance criteria tape stripping FDA guidance
This study was supported by the Biopharmaceutics Research Institute (BRI), Rhodes University, South Africa, and Dr. Prabhakar Kore Basic Sciences Research Center (BSRC), KLE University, Belgaum, India.
- 1.CDER. FDA. Guidance for Industry. Topical dermatologic corticosteroids: In vivo bioequivalence. June 1995. https://www.fda.gov/ohrms/dockets/dockets/04p0206/04p-0206-ref0001-08-FDA-Guidance-for-Industry-06-1995-vol3.pdf. Accessed 22 October 2017.
- 2.Office of Generic Drugs (OGD), FDA. Draft guidance on acyclovir, Recommended March 2012, https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm296733.pdf . Accessed 18 October 2017.
- 3.Office of Generic Drugs (OGD), FDA. Draft guidance on acyclovir, Recommended December 2014; Revised December 2016 https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428195.pdf . Accessed 22 October 2017.
- 4.Office of Generic Drugs (OGD), FDA. Draft guidance on dapsone gel, Recommended Dec 2014; Revised October 2017, https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428205.pdf) Accessed 22 October 2017.
- 5.Office of Generic Drugs (OGD), FDA. Draft guidance on docosanol cream, Recommended Oct 2017, (https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM572999.pdf) Accessed 22 October 2017.
- 6.Office of Generic Drugs (OGD), FDA. Draft guidance on ivermectin cream, Recommended Oct 2017, https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM573031.pdf Accessed 22 October 2017
- 7.Topical drug bioavailability, bioequivalence and penetration. Shah VP and Maibach HI, editors. Ist ed. Part III, In vivo methodology, Chapters 7–12, New York, 1993, Plenum Press. 129-219Google Scholar
- 8.Kanfer I, Methods for the assessment of bioequivalence of topical dosage forms: correlations, optimization strategies, and innovative approaches. Topical drug bioavailability, bioequivalence, and penetration. Shah VP, Maibach HI, Jenner J, editors. 2nd ed. New York, Springer Science+Business media. 113–151.Google Scholar
- 10.Bodenlenz M, Tiffner KI, Raml R, Augustin T, Dragatin C, Birngruber T, et al. Open flow microperfusion as a dermal pharmacokinetic approach to evaluate topical bioequivalence. Clin Pharmacokinet. 2017;56:91–8. https://doi.org/10.1007/s40262-016-0442-z. 2016.
- 11.US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research. Guidance for industry topical dermatological drug product NDAs and ANDAs—in vivo bioavailability, bioequivalence, in vitro release, and associated studies DRAFT GUIDANCE. Food and Drug Administration, Rockville.1998.Google Scholar
- 12.US Food and Drug Administration, HHS. Dermatological drug product NDAs and ANDAs—in vivo bioavailability, bioequivalence, in vitro release and associated studies; Withdrawal. Federal Register. 17 May 2002, 67(96); 35122–35123.Google Scholar
- 24.World Medical Association. WMA Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/Accessed 04Jun 2016.
- 26.Evaluation and licensing division of the Pharmaceutical and Food Safety Bureau of ministry of Health, Labour and welfare, Japan. Yakushokushinsahatsu Notification 1124004, dated November 24, 2006.Google Scholar
- 28.CDER. U.S. Department of Health and Human Services, FDA, Guidance for Industry, bioavailability and bioequivalence studies for orally administered drug products-General considerations. 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-BioEquiv.pdf Accessed 04Jun 2016.